Search Results - "Novak, L B"

  • Showing 1 - 9 results of 9
Refine Results
  1. 1

    Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram by Underwood, D C, Osborn, R R, Novak, L B, Matthews, J K, Newsholme, S J, Undem, B J, Hand, J M, Torphy, T J

    “…Selective inhibition of the low Km cyclic AMP-specific phosphodiesterase has been shown to inhibit inflammatory cell function and relax airway smooth muscle…”
    Get more information
    Journal Article
  2. 2

    Regiospecific intestinal absorption of the HIV protease inhibitor L-735,524 in beagle dogs by KWEI, G. Y, NOVAK, L. B, HETTRICK, L. A, REISS, E. R, OSTOVIC, D, LOPER, A. E, LUI, C. Y, HIGGINS, R. J, I-WU CHEN, LIN, J. H

    Published in Pharmaceutical research (01-06-1995)
    “…To evaluate regional intestinal absorption and the feasibility of sustained release dosage form development for an HIV protease inhibitor, L-735,524, L-735,524…”
    Get full text
    Journal Article
  3. 3

    Catecholamine and beta-adrenoceptor influences on airway reactivity to antigen in guinea pigs by Underwood, D C, Matthews, J K, Osborn, R R, Novak, L B, Bochnowicz, S, Meunier, L D

    “…The aim of the present study was to analyze the increased airway reactivity to antigen induced by beta-adrenoceptor blockade, adrenalectomy or medullectomy and…”
    Get more information
    Journal Article
  4. 4

    Lymphatic uptake of MK-386, a sterol 5 α-reductase inhibitor, from aqueous and lipid formulations by Kwei, Gloria Y, Novak, Linda B, Hettrick, Lisa H, Reiss, Elisabeth R, Fong, Eva K, Olah, Timothy V, Loper, Alice E

    Published in International journal of pharmaceutics (13-04-1998)
    “…4,7- β-Dimethyl-4-aza-5 α-cholestan-3-one (MK-386) is a specific inhibitor of type-1 5 α-reductase, with over 10 4-fold greater solubility in lipid-type…”
    Get full text
    Journal Article
  5. 5
  6. 6

    A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro by Hugger, Erin D, Novak, Barbara L, Burton, Philip S, Audus, Kenneth L, Borchardt, Ronald T

    Published in Journal of pharmaceutical sciences (01-09-2002)
    “…P-glycoprotein (P-gp), a multidrug resistance (MDR) protein encoded by the MDR1 gene in humans, is responsible for the efflux of structurally diverse drugs…”
    Get more information
    Journal Article
  7. 7

    Erythropoietin‐Induced Hypertensive Urgency in a Patient with Chronic Renal Insufficiency: Case Report and Review of the Literature by Novak, Barbara L., Force, Rex W., Mumford, Brett T., Solbrig, Ronald M.

    Published in Pharmacotherapy (01-02-2003)
    “…Hypertension is a potentially dangerous side effect of erythropoietin treatment; however, extreme elevations in blood pressure are rare. A 75‐year‐old woman…”
    Get full text
    Journal Article
  8. 8

    Detriments of tPA for acute stroke in routine clinical practice by Novak, Barbara L, Force, Rex W

    Published in The Journal of family practice (01-02-2003)
    “…Under optimal conditions, tissue plasminogen activator (tPA) may be a viable option for treatment of acute ischemic stroke; however, this study showed that…”
    Get full text
    Journal Article
  9. 9